| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
ABVC BioPharma, Inc.$1.9
+0.1 (+5.56%)
D 30Pipeline Score Overvalued Pharma · Clinical
Market Cap
32.50 M
EPS
-0.39
P/E Ratio
-3.21 $
Value Trade
170.22 K
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
33.10 K
Operating CF
-894.24 K
Total Assets
19.73 M
Total Liabilities
6.90 M
Equity
10.77 M
D/E Ratio
12,345
5.56 %
Week
-10.24 %
1 Month
-25 %
3 Month
-57.93 %
6 Month
-97.89 %
5 Year
-100 %
All Time
Cash Data
Cash Position
202.51 K
Monthly Burn
298.00 K
Runway
0 mo
Burn Trend
SEC Filing
May 18, 2026
Overview
Volume
325.06 K
52 Week Range
0.88 - 5.48
% held by Insiders
18.57 %
% held by Institutions
3.14 %
Enterprise Value
37.09 M
Total Shares
25.45 M
Short %
1.85 %
Float Shares
20.61 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for ABVC BioPharma, Inc.
158Total events
0Upcoming
41Tier-1 (high impact)
2006 – 2026Coverage
Event history 158
Mar 3, 2026
●Quarterly UpdateCorporate
Filed Annual Report on Form 10-K for fiscal year ended December 31, 2025
Aug 14, 2025
●Quarterly UpdateCorporate
Reported Q2 2025 financial results with diluted loss per share of $(0.13)
Jul 2025
▲Partnership / LicenseCorporate
Received $350,000 in licensing revenue from AiBtl BioPharma, OncoX BioPharma, and ForSeeCon Eye Corporation in July 2025
Jun 2025
●AcquisitionCorporate
Completed acquisition of farmland in Taiwan valued at ~$3.3 million for R&D and GMP expansion
Apr 16, 2025
▲Quarterly UpdateCorporate
Announced 2024 financial results with revenue up 234%, expenses down 21%, EPS improvement of 77%
Jan 13, 2025
▲Quarterly UpdateCorporate
Nasdaq granted additional 180-day grace period to regain bid price compliance
Q4 2024
2024
▲Trial InitiationABV-1601Trial
Phase I study for ABV-1601 to initiate by end of 2024
MDD in cancer patientssource ↗
Drug Pipeline Intelligence
D30
Pipeline Score $10M
Pipeline ValueOvervalued
Valuation Signal3
Drugs Scored0.3x
rNPV / MCap Top 34%
Micro Cap (rank 599 of 906)
Percentile RankABVC BioPharma, Inc. faces pipeline headwinds (30/100), with $1.6B risk-adjusted pipeline value, led by BLEX 404 Liquid in Myelodysplastic Syndrome (MDS) (Phase 2), but cash runway is a concern.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BLEX 404 Liquid Small molecule | Myelodysplastic Syndrome (MDS) | Phase 2 | NCT02944955 | 60% | $821M | NOT YET_RECRUITING | 52 | - | D (30) | Dec 31, 2028 | - | MEDIUM May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ABVC
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
ABVC Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
ABVCABVC BioPharma Reports 2025 Form 10-K Total Assets Increase 179% to $21.06 Million as Company Strengthens Asset-Backed Licensing Model Silicon Valley, CA (
ABVC BioPharma reported a significant increase in total assets, rising 179% to $21.06 million for the fiscal year ended December 31, 2025, according to their Form 10-K filing. The company emphasizes its strategic acquisition of land assets in Asia as a cornerstone of its asset-backed licensing model. This approach is designed to separate development risks from long-term value, enhancing the financial efficiency of the company. ABVC BioPharma aims to evolve towards a hybrid asset model that combines real assets with its existing intellectual property-driven framework.
Read more →ABVCABVC BioPharma Reports 230% YoY Licensing Revenue Growth and 181% Asset Expansion in Q3 2025 Silicon Valley, CA (
ABVC BioPharma reported impressive financial results for Q3 2025, highlighting a 230% increase in year-over-year licensing revenue and a 181% expansion in assets. The company's focus on an asset-light business model has allowed it to pursue growth through partnerships and collaborations, particularly in the central nervous system, ophthalmology, and oncology sectors. CEO Dr. Uttam Patil expressed confidence in the company’s strategic priorities aimed at long-term shareholder value. ABVC's active pipeline includes six drugs and one medical device currently under development.
Read more →ABVCABVC BioPharma, Inc. Reports 103% Year-Over-Year Asset Growth and Secures $350K in Post-Quarter Licensing Revenue in Q2 2025 Silicon Valley, CA (
ABVC BioPharma, Inc. has reported a significant 103% increase in year-over-year assets and secured $350,000 in licensing revenue in July 2025. The company's second-quarter results show a reduced diluted loss per share, reflecting its focus on operational efficiency. ABVC's recent acquisition of farmland in Taiwan aims to support its research and manufacturing capabilities in Asia. The CEO highlighted these initiatives as part of the company's strategy for sustainable long-term growth and enhancing shareholder value.
Read more →ABVCABVC BioPharma Regains Nasdaq Minimum Bid Price Compliance Silicon Valley, CA
ABVC BioPharma has successfully regained compliance with Nasdaq's minimum bid price, confirming a closing bid price above $1.00 for 10 consecutive trading days. This achievement highlights the company's turnaround strategy and commitment to enhancing shareholder value. Additionally, ABVC is entering discussions with major pharmaceutical and AI firms for the co-development of its Phase III-ready candidates for Major Depressive Disorder and ADHD. The company is focusing on building a platform for future commercialization while maintaining high listing standards.
Read more →ABVCABVC BioPharma Announces First Quarter 2025 Financial Results and Strategic Planning for AI-Driven Agricultural Project in Taiwan Silicon Valley, CA
ABVC BioPharma announced its financial results for Q1 2025 and outlined plans for a potential AI-enabled agricultural project in Taiwan. The company recognized a land asset valued at $7.67 million for this development, which aims to enhance agricultural practices through precision technology. Despite optimistic projections, the company acknowledges that the project's realization is uncertain. Additionally, financial data reflects a significant operating loss compared to the previous year, highlighting ongoing challenges as the company seeks to enhance its drug pipeline and infrastructure.
Read more →ABVCABVC BioPharma Announces 2024 Financial Results Revenue Surges 234%, Expenses Down 21%, EPS Improves 77%, with Over $18.3 Million 1 Licensing Incomes Available Silicon Valley , CA (
ABVC BioPharma announced its financial results for the fiscal year ended December 31, 2024, highlighting a significant revenue growth of 234% to $509,589, primarily driven by licensing payments. Expenses also decreased by 21% to $5.21 million, showcasing improved cost management. Moreover, the company's earnings per share improved by 77%, with a narrower net loss of $4.90 million. ABVC has the potential to receive up to $18.3 million in additional milestone payments under its current licensing agreements, enhancing its growth prospects.
Read more →ABVCABVC BioPharma, Inc. Granted Additional 180-Day Grace Period to Regain Compliance with Nasdaq Bid Price Requirement Fremont, CA (
ABVC BioPharma, Inc. has been granted an additional 180-day grace period by Nasdaq to meet its minimum bid price requirement, extending the deadline to July 7, 2025. The company is committed to regaining compliance by monitoring its stock price and taking necessary steps during this period. ABVC has shown compliance with all other Nasdaq listing requirements and is optimistic about its future growth and development plans.
Read more →ABVCABVC BioPharma Inc. Reports Q3 2024 Financial Results and Operational Milestones ABVC BioPharma Achieved its First Operational Profit, with a 102% Improvement over the Third Quarter of Last Year. Incremental Payments Rec
ABVC BioPharma, Inc. reported its Q3 2024 financial results, achieving its first operational profit and a 102% improvement compared to the prior year. The company is advancing in clinical trials for its major depressive disorder and ADHD programs, with important regulatory moves for its vitreous substitute, Vitargus. Recent licensing agreements have positioned ABVC to potentially generate significant revenue streams. Despite a negative EPS due to interest expenses, management expressed confidence in their growth trajectory and future value creation.
Read more →ABVCCorporate Overview NASDAQ: ABVC 2024 2 Forward Looking Statements This presentation contains summary information about ABVC BioPharma, Inc . ("ABVC") as of the date hereof . The information in this presentation is of gen
ABVC BioPharma has released an overview detailing its corporate strategy and financial performance for Q2 2024. The company reported a notable increase in revenue from $6,109 in Q2 2023 to $117,142 in the same quarter of 2024. Additionally, ABVC's earnings per share improved significantly. Its pipeline includes promising candidates for Major Depressive Disorder and ADHD, with recent advancements in patent approvals and licensing agreements suggesting positive future prospects.
Read more →ABVCABVC BioPharma Inc. Reports Strong Q2 2024 Financial Results and Strategic Achievements Executed Global Licensing Agreements that could provide up to $292 million in income Received Cash Milestone Incomes of $116,000 Ach
ABVC BioPharma Inc. reported strong financial results for Q2 2024, including significant licensing agreements that could provide up to $292 million in income. The company achieved an 86.8% year-over-year improvement in earnings per share and recorded substantial revenue growth. While the financial outlook appears promising, the potential income from licensing agreements remains contingent on product success. Recent patent approvals and advancements in clinical trials further bolster ABVC's strategic position in the biopharmaceutical market.
Read more →ABVCImmunity Boosting Combination Therapy for Myelodysplastic Syndrome Treatment: A Milestone Collaboration Between ABVC and OncoX, ABVC Eligible to Receive Aggregate Income of $13.75M and Royalties of up to $12.50M Fremont,
ABVC BioPharma has formed a significant collaboration with OncoX BioPharma to develop a combination therapy for Myelodysplastic Syndrome (MDS), announcing the potential for an aggregate income of $13.75M and royalties up to $12.50M. The partnership marks a hopeful advance in MDS treatment, aiming to improve patient outcomes through innovative therapeutic approaches. However, there are uncertainties regarding both the financial outcomes and the success of the therapy, as regulatory approvals and market dynamics remain unpredictable.
Read more →ABVCPromising Combination Therapy for Tripple Negative Breast Cancer Treatment: A Milestone Collaboration Between ABVC and OncoX, Potential Income of $13.75M and Royalties of up to $12.50M Fremont, CA (
ABVC BioPharma has announced a partnership with OncoX BioPharma to develop a combination therapy for Triple Negative Breast Cancer (TNBC). The collaboration includes a significant financial agreement potentially worth up to $13.75 million, along with royalties on future sales. This effort aims to improve treatment options for TNBC, a challenging subtype of breast cancer that currently lacks effective therapies. Both companies will contribute their expertise in drug development towards clinical trials and regulatory proceedings. However, the outcome and timeline for the therapy remain uncertain.
Read more →ABVCCombination Therapy Holds Promise for Pancreatic Cancer Treatment: A Milestone Collaboration Between ABVC and OncoX, ABVC Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M Fremont, CA (
ABVC BioPharma, in collaboration with OncoX BioPharma, announced a partnership to develop a combination therapy for pancreatic cancer. This collaboration includes a license fee of $12.5 million and milestone payments as part of their agreement, signaling a strong financial expectation from the partnership. The therapy aims to improve patient outcomes by leveraging the strengths of both companies in oncology treatment. However, uncertainties remain about the successful development and commercialization of the product, alongside potential challenges in financing and regulatory approvals.
Read more →ABVCABVC Biopharma Executes a Global Licensing Definitive Agreement for the Treatment of NSCLC, Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M Fremont, CA (
ABVC Biopharma has entered a global licensing agreement with OncoX to develop and distribute a botanical drug extract for treating Non-Small Cell Lung Cancer (NSCLC). The agreement anticipates an aggregate income of $13.75 million and royalties of up to $12.50 million, contingent on future sales. This collaboration is aimed at enhancing treatment options and expediting patient access to innovative therapies. Both companies will combine their strengths to advance the clinical program for the promising therapy BLEX 404.
Read more →ABVCABVC Biopharma Entered into a Global Licensing Deal of Vitargus with Licensing Income of $33.5M and Royalties up to $60M Fremont, CA (
ABVC Biopharma has entered a global licensing agreement with ForSeeCon Eye Corporation for its ophthalmology product, Vitargus. The deal includes an initial licensing payment of $30 million and royalties of up to $60 million based on future sales. ABVC's CEO highlights the potential to improve patient quality of life during vitrectomy procedures through this collaboration. This agreement positions ABVC to expand its reach in the ophthalmic market, which is projected to grow significantly over the next several years.
Read more →ABVCABVC BioPharma Reports Annual 2023 Financials and Provides Fiscal Year 2024 First Quarter Business Update Fremont, CA (
ABVC BioPharma has released its annual financial results for 2023, highlighting a commitment to improve health outcomes through botanically derived solutions. Significant developments include a global licensing agreement for CNS drugs, which positions the company toward profitability with potential royalties. Additionally, the company has regained Nasdaq compliance and expanded its patent portfolio for various health indications. However, concerns remain regarding its reliance on external financing and the impact of convertible notes on shareholder value.
Read more →ABVCABVC Acquires $2.96 Million Worth of Land in Asia with Stocks Priced at $3.50 per Share Fremont, CA
ABVC BioPharma has signed an agreement to acquire real estate in Taoyuan City, Taiwan, valued at approximately $2.96 million. The acquisition, executed through an equity transfer at a price of $3.50 per share, is intended to support the development of plant factories to grow raw materials for ABVC's botanical drug pipeline. This investment is viewed as an opportunity to enhance shareholder equity and foster collaborations in the Asian healthcare market. The transaction involves a related party, which may introduce governance considerations but reflects strategic positioning in a growing sector.
Read more →ABVCABVC BioPharma Reports Third Quarter 2023 Financial and Operational Results FREMONT, CA
ABVC BioPharma reported its third-quarter financial and operational results, showcasing progress in clinical trials and strategic partnerships. The company announced successful Phase II trial results for its drug ABV-1504 aimed at treating Major Depressive Disorder, with plans for a Phase III meeting with the FDA. It has also formed a licensing agreement with Xinnovation for its ADHD and MDD drugs, which could yield up to $20 million. The establishment of a partnership with Zhonghui for a health initiative in China was also highlighted.
Read more →ABVCABVC Executes Cooperation Agreement for Strategic Investments Fremont, CA
ABVC BioPharma, Inc. has announced a Cooperation Agreement with Zhonghui United Technology to exchange a 20% ownership stake in a real estate property. Valued at approximately $7.4 million, this agreement will support the establishment of a healthcare center focusing on senior living and various medical care areas. The collaboration aims to contribute to rural revitalization and foster innovation in ABVC's target fields, including Oncology and Ophthalmology. This partnership signifies ABVC's commitment to company growth and global expansion in the biopharmaceutical sector.
Read more →ABVCABVC BioPharma Regains Compliance with Nasdaq's Minimum Bid Price Requirement Fremont, CA (
ABVC BioPharma has announced that it has regained compliance with Nasdaq's minimum bid price requirement, as it managed to maintain a closing bid price of $1.00 per share from July 25 to August 7, 2023. This compliance followed a notification in August 2022, when the company was warned of its non-compliance. ABVC is a clinical-stage biopharmaceutical company with an active pipeline that includes six drug candidates and one medical device. The company aims to conduct further clinical trials leveraging technology from esteemed research institutions to optimize product development.
Read more →ABVCABVC Corporate Update and CEO's Letter to Shareholders Fremont, CA (
ABVC BioPharma has undergone significant transformation under new CEO Dr. Uttam Patil, highlighting recent advancements in its clinical pipeline. Notable developments include the progression of trials for major depressive disorder and ADHD, as well as the innovative Vitargus product for retinal surgeries. A strategic licensing agreement with Xinnovation Therapeutics offers potential revenue of $20 million. Additionally, ABVC is advancing its manufacturing capabilities and preparing for upcoming clinical trials.
Read more →ABVCABVC Signs a Term Sheet to Earn Licensing Fees of up to $20M and Royalties of 5-12% of Net Sales Fremont, CA (
ABVC Biopharma has signed a term sheet with Chinese pharmaceutical company Xinnovation Therapeutics for the exclusive licensing of its drugs ABV-1504 and ABV-1505, targeting Major Depressive Disorder and ADHD. This agreement, subject to definitive terms, could provide ABVC with licensing fees of up to $20 million and royalty payments based on sales in China. The collaboration leverages Xinnovation's capabilities to navigate regulatory requirements and market these innovative therapies in a growing region. The final agreement is expected to be formalized within a year, contingent on specific closing conditions.
Read more →ABVCABVC BioPharma Announces Closing on $1.75 Million Registered Direct Offering Fremont, CA (
ABVC BioPharma has successfully completed a $1.75 million registered direct offering with a single institutional investor. The company sold 500,000 shares of common stock at $3.50 each, expecting the proceeds to fuel research and development as well as working capital needs. ABVC continues to focus on therapeutic solutions in ophthalmology, neurology, and oncology/hematology, backed by positive market potential predictions for their pipeline. The offering was executed according to SEC regulations and included both common stock and pre-funded warrants.
Read more →ABVCABVC BioPharma Announces Pricing of $1.75 Million Registered Direct Offering Fremont, CA (
ABVC BioPharma has announced a $1.75 million registered direct offering of common stock, selling 500,000 shares at $3.50 each. The proceeds will be used for research and development activities and general corporate purposes. The offering is expected to close by July 31, 2023, pending customary closing conditions. ABVC BioPharma's initiatives reflect a commitment to expand its portfolio in therapeutic areas like ophthalmology, neurology, and oncology/hematology.
Read more →ABVCABVC BioPharma Announces Reverse Stock Split Fremont, CA (
ABVC BioPharma has announced a 1-for-10 reverse stock split effective July 25, 2023, as part of its efforts to comply with Nasdaq listing requirements. This decision follows shareholder approval and aims to decrease the number of outstanding shares while potentially increasing the market price. The company emphasizes that this split will not affect stockholder rights and aims to attract more investors to support its research activities.
Read more →ABVCCor p orate Overview N A SD A Q: ABVC 2023 This presentation contains summary information about ABVC BioPharma, Inc . ("ABVC") as of the date hereof . The information in this presentation is of general background and con
ABVC BioPharma, Inc. presented an overview of its pipeline and corporate activities as of 2023. The presentation outlined the company's strategy of in-licensing promising compounds to advance their clinical trials, notably with its Vitargus product. ABVC reported progress in its clinical studies, including the completion of several Phase II trials. However, it also cautioned potential investors about the risks and uncertainties inherent in its forward-looking statements and the impossibility of guaranteeing outcomes based on past performance.
Read more →ABVCABVC BioPharma Announces Fiscal Year 2022 Financial and Operational Results FREMONT, CA
ABVC BioPharma has announced its financial and operational results for the fiscal year 2022. The company is advancing its clinical pipeline with planned Phase II trials for its biodegradable vitreous substitute, Vitargus, expected to conclude in 2023. Additionally, ABV-1505 for ADHD and ABV-1601 for cancer patient depression are both in ongoing clinical studies. ABVC is optimistic about expanding its product pipeline and aims to seek partnerships following the progress of its trials.
Read more →ABVCABVC BioPharma Receives $3.175 Million Investment from The Lind Partners to Continue Clinical Trials Fremont, CA (
ABVC BioPharma has announced a $3.175 million investment from The Lind Partners to further its clinical trials. The funding will primarily support Phase II trials for its medical device, Vitargus, and its ADHD treatment, ABV-1505. The CEO of ABVC expressed optimism about the potential impact of this investment on the company's growth and drug development initiatives. The investment reflects confidence from The Lind Partners in ABVC's prospects for the upcoming year.
Read more →ABVCABVC Biopharma Announces Letter to Shareholders FREMONT, CA
ABVC Biopharma Announces Letter to Shareholders FREMONT, CA, September 13, 2022 - ABVC BioPharma, Inc. (Nasdaq: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced a letter to shareh
Read more →ABVCABVC BioPharma Expands Co-Development Partnership with Rgene Corporation Fremont, CA (
ABVC BioPharma Expands Co-Development Partnership with Rgene Corporation Fremont, CA (June 21, 2022) - ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announ
Read more →ABVCABVC BioPharma, Inc. Announces $4.22 Million Registered Direct Offering Fremont, California
BioPharma, Inc. Announces $4.22 Million Registered Direct Offering California, May 12, 2022 (GLOBE NEWSWIRE) -- ABVC BioPharma, Inc. ("ABVC" or the "Company") (NASDAQ: ABVC), today announced that it has entered into securities purchase agreements with certain institutional inve
Read more →ABVCABVC BIOPHARMA, INC. 44370 Old Warm Springs Blvd., Fremont, CA 94538 NOTICE OF 2022 ANNUAL MEETING OF SHAREHOLDERS To the Shareholders of ABVC BioPharma, Inc.: You are cordially invited to attend the 2022 annual sharehol
Old Warm Springs Blvd., Fremont, CA 94538 OF 2022 ANNUAL MEETING OF SHAREHOLDERS the Shareholders of ABVC BioPharma, Inc.: are cordially invited to attend the 2022 annual shareholder meeting of ABVC BioPharma, Inc. (the "Company" or "ABVC") to be held on May 20, 2022 at 9:00
Read more →ABVCABVC Biopharma Announces Fiscal Year 2021 Financial and Operational Results FREMONT, CA
ABVC Biopharma Announces Fiscal Year 2021 Financial and Operational Results FREMONT, CA, March 31, 2022 -- ABVC BioPharma, Inc. (Nasdaq: ABVC), a biotechnology company specializing in botanically based solutions that seeks to deliver high efficacy with low toxicity for improv
Read more →ABVCABVC BioPharma, Inc. Announces Pricing of $6.875 Million Firm Commitment Offering Will Trade on the NASDAQ Capital Market Under the Ticker "ABVC" FREMONT, CA (
ABVC BioPharma, Inc. Announces Pricing of $6.875 Million Firm Commitment Offering Will Trade on the NASDAQ Capital Market Under the FREMONT, CA (August 3, 2021) - ABVC BioPharma, Inc., a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hem
Read more →ABVCAMERICAN BRIVISION (HOLDING) CORPORATION 44370 Old Warm Springs Blvd. Fremont, CA 94538 (845) 291-1291 TO THE SHAREHOLDERS OF AMERICAN BRIVISION (HOLDING) CORPORATION: You are cordially invited to attend the 2021 annual
AMERICAN BRIVISION (HOLDING) CORPORATION 44370 Old Warm Springs Blvd. TO THE SHAREHOLDERS OF AMERICAN BRIVISION (HOLDING) CORPORATION: You are cordially invited to attend the 2021 annual shareholder meeting of American BriVision (Holding) Corporation (the "Company" or "ABVC")
Read more →ABVChttp://abvcpharma.com/ 44370 Old Warm Springs Blvd. Fremont, CA 94538 Dear Shareholder: Now that 2020 has ended, we believe it will be informative to you, our shareholders, to hear about our goals for 2021. But first, we
Now that 2020 has ended, we believe it will be informative to you, our shareholders, to hear about our goals for 2021. But first, we note that 2020 was an exceptional year for the company, particularly with respect to our medical device, Vitargus , and our medicine ABV-1505, wh
Read more →ABVCDear Investors, As the ABVC team works diligently to have our shares uplisted and trading on a senior exchange as soon as possible , we would like to take this opportunity to review our progress to date: ABVC Recently th
As the ABVC team works diligently to have our shares uplisted and trading on a senior exchange as soon as possible, we would like to take this opportunity to review our progress to date: Recently there were two news releases about ABVC. The first one, released on April 13, 20
Read more →ABVCAmerican BriVision Announces Two Financial Transactions To Improve Working Capital and Reduce Debt FREMONT, CA (
BriVision Announces Two Financial Transactions To Improve Working Capital and Reduce Debt FREMONT, CA (April 13, 2020) - American BriVision (Holding) Corporation (OTCQB: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology,
Read more →ABVCAmerican BriVision Initiates Phase II Part I Clinical Trial for ABV-1505 in Adult Attention-Deficit Hyperactivity Disorder (ADHD) GlobeNewswire
BriVision Initiates Phase II Part I Clinical Trial for ABV-1505 in Adult Attention-Deficit Hyperactivity Disorder (ADHD) GlobeNewswire December FREMONT, CA, Dec. 05, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- American BriVision (Holding) Corporation (ABVC) (the "Company"), a
Read more →ABVCAmerican BriVision Highlights Results from Vitargus First-in-Human Clinical Trial Dr. Andrew Chang, principal investigator, recently presented encouraging feasibility study results from Vitargus at the AAO 2019 Annual Me
Highlights Results from Vitargus First-in-Human Clinical Trial FREMONT, CA (October 15, 2019) - American BriVision (Holding) Corporation (OTCQB: ABVC) (the "Company"), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and
Read more →ABVCAmerican BriVision Announces Vitargus Presentation at Upcoming AAO 2019 Annual Meeting GlobeNewswire
Announces Vitargus Presentation at Upcoming AAO 2019 Annual Meeting GlobeNewswire- October 10, 2019 FREMONT, CA, Oct. 10, 2019 (GLOBE NEWSWIRE) - via NEWMEDIAWIRE - American BriVision (Holding) Corporation (ABVC) (the "Company"), a clinical stage biopharmaceutical company dev
Read more →ABVCof Independent Registered Public Accounting Firm
of Independent Registered Public Accounting Firm the Board of Directors and Shareholders of BioLite Holding, Inc. on the Financial Statements have audited the accompanying consolidated balance sheets of BioLite Holding, Inc. and its subsidiaries. ( collectively referred to as
Read more →ABVCCO-DEVELOPMENT AGREEMENT Made and entered as of this 26th day of May 2017 ("the Effective Date") BY AND BETWEEN American BriVision Corporation , a company incorporated under the laws of USA and having it principle place
and entered as of this 26th day of May 2017 ("the Effective Date") BriVision Corporation, a company incorporated under the laws of USA and having it principle place of business at 11 Sawyers Peak Drive, Goshen, NY 10924 USA ("ABVC") Corporation, a company incorporated under th
Read more →ABVCADDENDUM This ADDENDUM (this " Addendum ") dated January 12 th , 2017 (the " Effective Date ") to the Collaborative Agreement dated
ADDENDUM (this "Addendum") dated January 12th , 2017 (the "Effective Date") to the Collaborative Agreement dated December 29, 2015 (as amended hereby, the "Agreement") by and between BioLite, Inc., a company incorporated under the laws of Taiwan and having its principal place o
Read more →ABVC10/2015 COLLABORATIVE AGREEMENT Made and entered into as of this 29th day of December 2015 ( the Effective Date ) BY AND BETWEEN BioLite Inc ., a company incorporated under the laws of Taiwan and having its principal pla
COLLABORATIVE AGREEMENT Made and entered into as of this 29th day of December 2015 ("the Effective Date") BioLite Inc., a company incorporated under the laws of Taiwan and having its principal place of business at 3rd Floor, 248, Nei-Hu Road, Sec. 1, Taipei, 11493 Taiwan ("Bi
Read more →ABVCDonald C. Campion 3747 Loch Bend Drive Commerce, Michigan 48382 (248) 360-8105 Fax (248) 360-4120
3747 Loch Bend Drive Commerce, Michigan 48382 Richard D. Stromback Ecology Coatings, Inc. Bloomfield Hills, MI 48304 This is to inform you that I am resigning from the Board of Directors of Ecology Coatings, effective immediately. The reason for my decision to resign is la
Read more →ABVCImportant News From Ecology Coatings Cleantechnology Paper Coatings Achieves Toxic Mold Inhibition Case Western Reserve University Study Confirms Paper Coating Technology Capability to Inhibit Black Mold Formation on Wal
Ecology Coatings Cleantechnology Paper Coatings Achieves Toxic Mold Inhibition Case Western Reserve University Study Confirms Paper Coating Technology Capability to Inhibit Black Mold Formation on Wallboard a $6 Billion Industry Hills, MI April 16, 2008 Ecology Coatings, Inc.
Read more →ABVCexv99w1 Ecology Coatings Announces Awarding of Fifth U.S. Patent Latest Patent Protects Manufacturing Process and Methods for Environmentally Friendly Coating Used On a Wide Variety of Composite Materials B
Ecology Coatings Announces Awarding of Fifth U.S. Patent Latest Patent Protects Manufacturing Process and Methods for Environmentally Friendly Coating Used On a Wide Variety of Composite Materials Hills, MI February 14, 2008 Ecology Coatings, Inc. (OTCBB:ECOC), a leader in the
Read more →ABVCPRESENTATION MATERIALS exv99w1 Award-Winning Technology Stock Symbol: OTCBB:ECOC October 2007 With the exception of historical information, matters discussed in this presentation regarding product development, target mar
PZD has outperformed the Russell 2000 Stock Index by 25% over the past 12 months. Summary Investment in cleantech companies is accelerating at a rapid pace, exceeding that of the American economy as a whole by a wide measure. The market performance of cleantech companies signific
Read more →ABVCTwo Key Board Additions at Ecology Coatings Lend Expertise in Strategic Financial Growth and International Markets Veteran Financial Executive and Global Corporate Leader Join Green Industrial Coatings Team Bloomfield Hi
Two Key Board Additions at Ecology Coatings Lend Expertise in Strategic Financial Growth and International Markets Veteran Financial Executive and Global Corporate Leader Join Green Industrial Bloomfield Hills, Mich. August 28, 2007 Ecology Coatings, Inc. (OTCBB: ECOC), a lead
Read more →ABVCPress Contact: Alanna Gino, Antenna Group (for Ecology Coatings) 415-977-1918 alanna@antennagroup.com Ecology Coatings Names Chairman Richard Stromback as
Alanna Gino, Antenna Group (for Ecology Coatings) alanna@antennagroup.com Ecology Coatings Names Chairman Richard Stromback as CEO HILLS, Mich. August 15, 2007 Ecology Coatings, Inc. (OTCBB: ECOC), a leader in the development of nano-enabled, ultra-violet (UV) curable, clean
Read more →ABVC(ECOLOGYCOATINGS LOGO) ECOLOGY COATINGS, INC. COMPLETES REVERSE MERGER WITH OCIS CORPORATION Green Coatings Leader Begins Trading Under New Symbol (OTCBB: ECOC,) Expands Executive Team
(ECOLOGYCOATINGS LOGO) ECOLOGY COATINGS, INC. COMPLETES REVERSE MERGER WITH OCIS CORPORATION Green Coatings Leader Begins Trading Under New Symbol (OTCBB: ECOC,) Expands Executive Team BLOOMFIELD HILLS, Mich. - July 30, 2007 - ECOLOGY COATINGS, INC. (OTCBB: ECOC), the global
Read more →ABVCPress Contact: Rosalind Jackson Antenna Group (for Ecology Coatings) 415-977-1923 rosalind@antennagroup.com Ecology Coatings, Inc. Plans to be Publicly Held Nano-Enabled Clean Coatings Company Signs Letter of Intent for
Antenna Group (for Ecology Coatings) rosalind@antennagroup.com Ecology Coatings, Inc. Plans to be Publicly Held Nano-Enabled Clean Coatings Company Signs Letter of Intent for APO Akron, Ohio - November 7, 2006 - Ecology Coatings, Inc., a leading developer of nano- engineered
Read more →Competitive Position
How ABVC ranks across every disease it competes inCompetitive Position is a premium feature
See how ABVC ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial